Cancer risk, screening, and care gaps spotlight ACS's ongoing mission to fight cancer nationwide. The ACS is a long-standing U.S. nonprofit funding research and publishing journals.
A roundup of recent cancer breakthroughs highlights new immunotherapies, targeted drugs and surgical-sparing treatments. The Independent reports on Scolyer’s pioneering work and a landmark NICE decision; The Guardian covers durvalumab’s promise in bladder cancer; Business Insider UK and Reuters summarize ASCO findings on pancreatic and colon cancers, among others.
The FDA has approved bemotrizinol (BEMT) for over‑the‑counter sunscreens, marking a modernization in U.S. UV protection. The ingredient absorbs both UVA and UVB rays, is photostable, and will debut as Parsol Shield before broader market adoption after an 18‑month exclusivity period. Industry and dermatology experts say the move could improve protection and user experience, though rollout and formulation timelines remain.